Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14993381 | 0.98 | TSHR (0.34) | TSHRLPAR3ALDH1A1LMNALPAR2 | |
| SCHEMBL1230177 | 0.87 | TSHR (0.44) | TSHRLPAR3ALDH1A1LMNALPAR2 | |
| SCHEMBL1228272 | 0.87 | TSHR (0.44) | TSHRLPAR3ALDH1A1LMNALPAR2 | |
| SCHEMBL959298 | 0.87 | TSHR (0.44) | TSHRLPAR3ALDH1A1LMNALPAR2 | |
| SCHEMBL6037409 | 0.87 | TSHR (0.44) | TSHRLPAR3ALDH1A1LMNALPAR2 | |
| SCHEMBL8510858 | 0.87 | TSHR (0.44) | TSHRLPAR3ALDH1A1LMNALPAR2 | |
| SCHEMBL1229831 | 0.87 | TSHR (0.44) | TSHRLPAR3ALDH1A1LMNALPAR2 | |
| SCHEMBL6037441 | 0.87 | TSHR (0.44) | TSHRLPAR3ALDH1A1LMNALPAR2 | |
| SCHEMBL964644 | 0.87 | TSHR (0.44) | TSHRLPAR3ALDH1A1LMNALPAR2 | |
| SCHEMBL6037408 | 0.87 | TSHR (0.44) | TSHRLPAR3ALDH1A1LMNALPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785726-B1 | ESTER-FUNCTIONAL SILANES AND THE PREPARATION AND USE THEREOF; AND USE OF IMINIUM COMPOUNDS AS PHASE TRANSFER CATALYSTS | DOW SILICONES CORP (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9518072-B2 | Ester-functional silanes and the preparation and use thereof; and use of iminium compounds as phase transfer catalysts | DOW CORNING CORPORATION (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150126676-A1 | Ester-Functional Silanes And The Preparation And Use Thereof; And Use Of Iminium Compounds As Phase Transfer Catalysts | DOW SILICONES CORPORATION | 2015-05-07 | — | — | US | disclosed |
| EP-2785726-A2 | ESTER-FUNCTIONAL SILANES AND THE PREPARATION AND USE THEREOF; AND USE OF IMINIUM COMPOUNDS AS PHASE TRANSFER CATALYSTS | Dow Corning Corporation (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013081820-A2 | ESTER-FUNCTIONAL SILANES AND THE PREPARATION AND USE THEREOF;AND USE OF IMINIUM COMPOUNDS AS PHASE TRANSFER CATALYSTS | DOW CORNING CORPORATION (US) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126676-A1 | Ester-Functional Silanes And The Preparation And Use Thereof; And Use Of Iminium Compounds As Phase Transfer Catalysts | ICMT, INTS9, HDHD5 | TSHR 4158/4885LPAR3 4717/4885ALDH1A1 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.